In this second edition of Post-Genomic Cardiology, developing and new technologies such as translational genomics, next generation sequencing (NGS), bioinformatics, and systems biology in molecular cardiology are assessed in light of their therapeutic potential. As new methods of mutation screening emerge, both for the genome and for the "epigenome, comprehensive understanding of the many mutations that underlie cardiovascular diseases and adverse drug reactions is within our reach. This book, written by respected cardiologist José Marín-García, features discussion on the Hap-Map: the largest international effort to date aiming to define the differences between our individual genomes. This unique reference further reviews and investigates genome sequences from our evolutionary relatives that could help us decipher the signals of genes, and offers a comprehensive and critical evaluation of regulatory elements from the complicated network of the background DNA. - Offers updated discussion of cutting-edge molecular techniques including new genomic sequencing / NGS / Hap-Map / bioinformatics / systems biology approaches - Analyzes mitochondria dynamics and their role in cardiac dysfunction, up-to-date analysis of cardio-protection, and cardio-metabolic syndrome - Presents recent translational studies, gene therapy, transplantation of stem cells, and pharmacological treatments in CVDs

Offering unique, comprehensive coverage of both basic science and clinical scenarios, Clinical Immunology: Principles and Practice, 6th Edition, brings you up to date with every aspect of this fast-changing field. It examines the molecular, cellular, and immunologic bases of immunologic diseases and their broader systemic implications; it also includes complete coverage of common and uncommon immunologic disorders. Updated with all the latest immunologic research and clinical implications, including breakthrough immunotherapies and molecular-based treatment protocols, this fully revised edition provides authoritative guidance from some of the most respected global leaders in immunology in one complete, well-illustrated volume. - Includes extensive revisions that reflect rapidly expanding research and clinical advances, including breakthrough drug and immunotherapies such as immune checkpoint inhibitors, immunotherapies for cancer, precision medicine, and transfusion medicine. - Contains new chapters on COVID-19, immune responses, and the role of the immune system; immunoregulatory deficiencies; immune checkpoints; CAR T cells, including new cellular-based immunotherapy; gene therapy, including CRISPR and gene selection; and a clinically focused chapter on asthma. - Provides new genetics content focused on data applications. - Addresses notable advances in key areas such as the importance of the microbiota to normal immune system development and to the pathogenesis of immunologic and inflammatory diseases; relationships between the innate and adaptive immune systems; progress in rapid and cost-effective genomics; cell signaling pathways and the structure of cell-surface molecules; and many more. - Covers hot topics such as the role of genetics and genomics in immune response and immunologic disease, atherosclerosis, recurrent fever syndromes, aging and deficiencies of innate immunity, the role of microbiota in normal immune system development and in the pathogenesis of immunologic and inflammatory diseases, and novel therapeutics. - Features a user-friendly format with color-coded boxes highlighting critical information on Key Concepts, Clinical Pearls, Clinical Relevance, and Therapeutic Principles. - Summarizes promising research and development anticipated over the next 5–10 years with "On the Horizon" boxes and discussions of translational research. - An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.

Kidney cancer imposes a significant cancer burden and its incidence continues to rise globally. Mortality in advanced kidney cancer remains high despite oncological, surgical and multimodal optimisation. Genetic associations, heterogeneity and limitations in early diagnosis through lack of optimal biomarkers add to the challenges. Over the last two decades there has been an exponential increase in diagnostic and therapeutic advances in the management of kidney cancer. The coupling of scientific advances in engineering and technology with oncological therapeutics has recently ushered a renewed optimism. The role of minimally invasive approaches through focal therapy and surgical extirpation using the robotic platform has been unprecedented and paramount. Virtual augmentation and mixed reality platforms have proved useful supplementary tools in surgical planning. The role of surgical simulation and training in development of surgeons with the optimal skill set is essential to provide optimal care. This book is the first in a series that explores the evolving trends in kidney cancer. The focus of the book is broad and includes topics ranging from immunotherapy to surgical simulation. Some chapters explore leading edge concepts while others capture the evolving trends and future concepts. The Editors aim to stimulate the readers to explore the key concepts and to encourage research and innovation along the main themes presented.

Signal transduction pathways are at the core of most biological processes and are critical regulators of heart physiology and pathophysiology. The heart is both a transmitter and dynamic receptor of a variety of intracellular and extracellular stimuli, playing a critical role of an integrator of diverse signaling mechanisms. Alterations in signaling pathways are contributing factors in the development and progression of a broad spectrum of diseases, ranging from dysrhythmias and atherosclerosis to hypertension and the metabolic syndrome. Targeting specific components of these signaling pathways has been shown to be effective in preclinical studies with significant therapeutic impact. This book brings together current knowledge in cardiovascular cell signal transduction mechanisms, advances in novel therapeutic approaches to improve cardiac function, and discussion of future directions. Presented from a post-genomic perspective, this exciting book introduces important new ideas in cardiovascular systems biology. It is an invaluable reference for cardiology researchers and practitioners.